The Global Anti-Addiction Market, 2008-2023

1 Executive Summary

2 Introduction: Worldwide Prevalence and Treatment of Addiction
2.1 The Physiology and Psychology of Addiction
2.1.1 Definition of Addiction
2.1.2 Addiction is Caused by Physical Dependence
2.1.3 Psychological Dependence
2.2 Prevalence of Addiction
2.3 Addiction Therapy
2.3.1 Behavioural Therapy
2.3.2 Addiction Treatment with Drugs
2.3.3 Off-Label Drug Prescribing for Addiction Therapy
2.4 Smoking Cessation Products
2.4.1 Nicotine Replacement Therapy (NRT)
2.4.2 Nicotine Replacement Therapy Products (Johnson & Johnson)
2.4.3 Nicotine Replacement Therapy Products (GSK)
2.4.4 Nicotine Replacement Therapy Products (Novartis)
2.4.5 Chantix/Champix (Pfizer)
2.4.6 Zyban (GSK/Biovail)
2.5 Obesity Drugs
2.5.1 Xenical (Roche)
2.5.2 Reductil/Meridia (Abbott Laboratories)
2.5.3 Alli (GSK)
2.5.4 Acomplia (Sanofi-Aventis)
2.5.5 Other Obesity Drugs
2.6 Drugs Used In Opioid Dependence
2.6.1 Suboxone/Subutex (Reckitt Benckiser/ Schering-Plough)
2.6.2 Methadone
2.6.3 Naltrexone
2.6.4 Other Drugs Used in Opioid Addiction Treatment
2.7 Alcohol Dependency Drugs
2.7.1 Campral/Aotal (Merck KGaA/Forest)
2.7.2 Antabuse (Barr)
2.7.3 Naltrexone
2.7.4 Vivitrol (Alkermes/Cephalon/Johnson & Johnson)
2.7.5 Revia (Barr/Bristol-Myers Squibb)

3 The Global Addiction Market
3.1 The Addiction Market in 2007
3.1.1 Leading Addiction Therapy Areas, 2007
3.1.2 Leading Addiction Brands, 2007
3.1.3 Leading Manufacturers of Addiction Drugs, 2007
3.2 Global Addiction Market Forecasts, 2008-2023
3.2.1 Addiction Market Forecast, 2008-2023
3.2.2 Addiction Therapy Area Sales Forecast, 2008-2023

4 The Global Smoking Cessation Market
4.1 The Smoking Cessation Market in 2007
4.1.1 Leading Smoking Cessation Product Types, 2007
4.1.2 Leading Manufacturers of Smoking Cessation Products, 2007
4.2 Smoking Cessation Market Forecasts, 2008-2023
4.2.1 Global Smoking Cessation Market Forecast, 2008-2023
4.2.2 Smoking Cessation Product Type Sales Forecast, 2008-2023
4.2.3 Chantix/Champix Sales Forecast, 2008-2023

5 The Global Obesity Market
5.1 The Obesity Market in 2007
5.1.1 Leading Obesity Brands, 2007
5.1.2 Leading Manufacturers of Obesity Drugs, 2007
5.2 Obesity Market Forecasts, 2008-2023
5.2.1 Global Obesity Market Forecast, 2008-2023
5.2.2 Xenical Sales Forecast, 2008-2023
5.2.3 Reductil/Meridia Sales Forecast 2008-2023
5.2.4 Alli Sales Forecast, 2008-2023
5.2.5 Acomplia Sales Forecast, 2008-2023

6 The Global Drug Addiction Market
6.1 The Drug Addiction Market in 2007
6.1.1 Leading Drug Addiction Product Types, 2007
6.1.2 Leading Manufacturers of Drug Addiction Products, 2007
6.2 Drug Addiction Market Forecasts, 2008-2023
6.2.1 Global Drug Addiction Market Forecast, 2008-2023
6.2.2 Drug Addiction Product Type Sales Forecast, 2008-2023
6.2.3 Suboxone/Subutex Sales Forecast, 2008-2023

7 The Global Alcohol Dependency Market
7.1 The Alcohol Dependency Market in 2007
7.1.1 Leading Alcohol Dependency Drug Types, 2007
7.1.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
7.2 Alcohol Dependency Market Forecasts, 2008-2023
7.2.1 Global Alcohol Dependency Market Forecast, 2008-2023
7.2.2 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
7.2.3 Campral/Aotal Forecast, 2008-2023
7.2.4 Vivitrol Sales Forecast, 2008-2023

8 Leading Addiction Country Markets
8.1 Top Twelve Addiction Country Markets, 2007
8.2 Addiction Market Country Forecasts, 2008-2023
8.3 The US Addiction Market
8.3.1 Prevalence of Addiction in the US
8.3.2 Smoking Cessation Dominated the US Addiction Market in 2007
8.3.3 Forecast for the US Addiction Market, 2008-2023
8.4 The UK Addiction Market
8.4.1 Prevalence of Addiction in the UK
8.4.2 There is Greater Reimbursement of Addiction Drugs in the UK Market
8.4.3 Forecast for the UK Addiction Market, 2008-2023
8.5 The French Addiction Market
8.5.1 Prevalence of Addiction in France
8.5.2 France has High Revenues in the Drug and Alcohol Addiction Markets
8.5.3 Forecast for the French Addiction Market, 2008-2023

9 SWOT Analysis of the Addiction Market
9.1 Analysis of the Market
9.2 Strengths of the Addiction Industry
9.2.1 Development of Addiction Vaccines and Novel Drug Formulations
9.2.2 Expansion into New Therapeutic Areas
9.3 Weaknesses of the Addiction Therapy Industry
9.3.1 Currently Marketed Addiction Therapies Lack Efficacy
9.3.2 Poor Patient Compliance
9.4 Opportunities in the Addiction Market
9.4.1 Addiction is Prevalent Worldwide and Increasing
9.4.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
9.4.3 Prevalence of Obesity Worldwide and in Major Country Markets
9.4.4 Prevalence of Drug Use Worldwide and in Major Country Markets
9.4.5 Alcohol Consumption and Dependence Worldwide and in Major
Country Markets
9.4.6 There is Considerable Under-Treatment of Patients
9.4.7 The Cost of Addiction is High
9.4.8 Awareness of the Costs of Addiction is Increasing
9.4.9 Smoking Legislation is Spreading
9.5 Threats to the Addiction Market
9.5.1 Reimbursement is the Key to Success in the Addiction Market
9.5.2 Concern over Side-Effects of Addiction Drugs
9.5.3 Behavioural Therapy is Often Preferred to Treatment with Drugs
9.5.4 Social Stigma and Lack of Education and Resources

10 The Addiction Therapy Pipeline
10.1 Some Areas of the Addiction Pipeline are Stronger than Others
10.2 The Smoking Cessation Product Pipeline
10.2.1 Addiction Vaccines Will Target Nicotine Dependence
10.2.2 Surinabant (Sanofi-Aventis)
10.2.3 EVT 302 (Evotec)
10.2.4 NicVAX (Nabi Biopharmaceuticals)
10.2.5 NIC002 (Cytos Biotechnology/Novartis)
10.2.6 TA-NIC (Celtic Pharma)
10.2.7 Niccine (Independent Pharmaceutica)
10.3 The Obesity Drug Pipeline
10.3.1 The Obesity Pipeline has had a High Failure Rate
10.3.2 Contrave (Orexigen)
10.3.3 CP-945598/Otenabant (Pfizer)
10.3.4 Lorcaserin (Arena)
10.3.5 Qnexa (Vivant)
10.3.6 ATL-962/Cetilistat (Alizyme/Takeda)
10.3.7 Pramlintide/Metreleptin (Amylin)
10.3.8 Histalean (OBEcure)
10.3.9 Empatic (Orexigen)
10.3.10 Liraglutide (Novo Nordisk)
10.4 The Drug Addiction Therapy Pipeline
10.4.1 Cocaine Treatment is the Most Promising Drug Addiction Pipeline Area
10.4.2 Vivitrol (Alkermes)
10.4.3 Probuphine (Titan)
10.4.4 TA-CD (Celtic Pharma)
10.4.5 SYN-117 (Synosia Therapeutics/Roche)
10.4.6 Lobeline (Yaupon Therapeutics)
10.4.7 Naltrexone Implant (Indevus)
10.4.8 Tetrodin (WEX Pharmaceuticals)
10.4.9 XY2401 (Xytis/National Institute on Drug Abuse/Rottapharm)
10.5 The Alcohol Dependency Therapy Pipeline
10.5.1 The Alcohol Dependency Pipeline Has Plenty of Room for Novel Products
10.5.2 Nalmefene (Biotie Therapies /Lundbeck/Somaxon): A New Drug for Dependency Disorders
10.5.3 Naltrexone Depot (Elbion NV)
10.5.4 ALKS 29 (Alkermes)
10.6 The Pipeline for Other Addiction Therapies

11 Expert Opinion from Key Opinion-Leaders in the Addiction Industry
11.1 Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals
11.1.1 Vaccines in the Pipeline for Nicotine Addiction
11.1.2 NicVAX
11.1.3 Other Nicotine Vaccines
11.2 Industry Representative from the Addiction Therapy Sector
11.2.1 Type of Addictions with Greatest Market Growth Potential
11.2.2 Key Unmet Needs For Alcohol Dependent Patients
11.2.3 Key Advantages of Nalmefene
11.2.4 The Future of the Alcohol Dependency Market

12 Conclusions
12.1 The Addiction Market in 2007
12.2 Opportunity for Growth in the Addiction Market
12.3 Visiongain's Forecast for the Addiction Market, 2008-2023

List of Tables
Table 2.1 Global Prevalence of Addiction and Drug Use
Table 2.2 Key Drugs Prescribed Off-Label for Addiction Therapy
Table 2.3 Major Johnson & Johnson Nicotine Replacement Therapy Brands
Table 2.4 Major GSK Nicotine Replacement Therapy Brands
Table 2.5 Major Novartis Nicotine Replacement Therapy Brands
Table 3.1 Leading Addiction Therapy Areas, 2007
Table 3.2 Leading Addiction Brands, 2007
Table 3.3 Leading Manufacturers of Addiction Drugs, 2007
Table 3.4 Global Addiction Market Forecast, 2008-2013
Table 3.5 Global Addiction Market Forecast, 2014-2023
Table 3.6 Addiction Therapy Area Sales Forecast, 2008-2013
Table 3.7 Addiction Therapy Area Sales Forecast, 2014-2023
Table 4.1 Leading Smoking Cessation Product Types, 2007
Table 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
Table 4.3 Global Smoking Cessation Market Forecast, 2008-2013
Table 4.4 Global Smoking Cessation Market Forecast, 2014-2023
Table 4.5 Smoking Cessation Product Type Sales Forecast, 2008-2013
Table 4.6 Smoking Cessation Product Type Sales Forecast, 2014-2023
Table 5.1 Leading Obesity Brands, 2007
Table 5.2 Leading Manufacturers of Obesity Drugs, 2007
Table 5.3 Global Obesity Market Forecast, 2008-2013
Table 5.4 Global Obesity Market Forecast, 2014-2023
Table 5.5 Obesity Brands Sales Forecasts, 2008-2013
Table 5.6 Obesity Brands Sales Forecasts, 2014-2023
Table 6.1 Leading Drug Addiction Product Types, 2007
Table 6.2 Leading Manufacturers of Drug Addiction Products, 2007
Table 6.3 Global Drug Addiction Market Forecast, 2008-2013
Table 6.4 Global Drug Addiction Market Forecast, 2014-2023
Table 6.5 Drug Addiction Product Type Sales Forecast, 2008-2013
Table 6.6 Drug Addiction Product Type Sales Forecast, 2014-2023
Table 6.7 Suboxone/Subutex Sales Forecast, 2008-2013
Table 6.8 Suboxone/Subutex Sales Forecast, 2014-2023
Table 7.1 Leading Alcohol Dependency Drug Types, 2007
Table 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
Table 7.3 Global Alcohol Dependency Market Forecast, 2008-2013
Table 7.4 Global Alcohol Dependency Market Forecast, 2014-2023
Table 7.5 Alcohol Dependency Drug Type Sales Forecast, 2008-2013
Table 7.6 Alcohol Dependency Drug Type Sales Forecast, 2014-2023
Table 7.7 Campral/Aotal and Vivitrol Sales Forecast, 2008-2013
Table 7.8 Campral/Aotal and Vivitrol Sales Forecast, 2014-2023
Table 8.1 Top Twelve Addiction Country Markets, 2007
Table 8.2 Addiction Market Country Forecasts, 2008-2013
Table 8.3 Addiction Market Country Forecasts, 2014-2023
Table 8.4 Prevalence of Addiction and Drug Use in the US
Table 8.5 The US Addiction Market, 2007
Table 8.6 Prevalence of Addiction and Drug Use in the UK
Table 8.7 The UK Addiction Market, 2007
Table 8.8 Prevalence of Addiction and Drug Use in France
Table 8.9 The French Addiction Market, 2007
Table 9.1 SWOT Chart for Addiction Market
Table 9.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
Table 9.3 Prevalence of Obesity Worldwide and in Major Country Markets
Table 9.4 Worldwide Drug Use, 2006/07
Table 9.5 Prevalence of Opioid Drug Use Worldwide and in Major Country Markets
Table 9.6 Prevalence of Cocaine Use Worldwide and in Major Country
Table 9.7 Alcohol Consumption & Dependence Worldwide & in Major Country Markets
Table 10.1 Key Smoking Cessation Pipeline Products
Table 10.2 Key Obesity Pipeline Drugs
Table 10.3 Key Drug Addiction Pipeline Therapies
Table 10.4 Key Alcohol Dependency Pipeline Drugs

List of Figures
Figure 3.1 Leading Addiction Therapy Areas, 2007
Figure 3.2 Leading Addiction Brands, 2007
Figure 3.3 Leading Manufacturers of Addiction Drugs, 2007
Figure 3.4 Global Addiction Market Forecast, 2008-2023
Figure 3.5 Addiction Therapy Area Sales Forecast, 2008-2023
Figure 3.6 Addiction Therapy Area Sales Forecast and Market Share, 2008-2023
Figure 3.7 Addiction Therapy Area Market Share, 2013
Figure 3.8 Addiction Therapy Area Market Share, 2018
Figure 3.9 Addiction Therapy Area Market Share, 2023
Figure 4.1 Leading Smoking Cessation Product Types, 2007
Figure 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
Figure 4.3 Global Smoking Cessation Market Forecast, 2008-2023
Figure 4.4 Smoking Cessation Product Type Sales Forecast, 2008-2023
Figure 4.5 Smoking Cessation Product Type Sales Forecast & Market Share, 2008-2023
Figure 4.6 Chantix/Champix Sales Forecast, 2008-2023
Figure 5.1 Leading Obesity Brands, 2007
Figure 5.2 Leading Manufacturers of Obesity Drugs, 2007
Figure 5.3 Global Obesity Market Forecast, 2008-2023
Figure 5.4 Xenical Sales Forecast, 2008-2023
Figure 5.5 Reductil/Meridia Sales Forecast, 2008-2023
Figure 5.6 Alli Sales Forecast, 2008-2023
Figure 5.7 Acomplia Sales Forecast, 2008-2023
Figure 6.1 Leading Drug Addiction Product Types, 2007
Figure 6.2 Leading Manufacturers of Drug Addiction Products, 2007
Figure 6.3 Global Drug Addiction Market Forecast, 2008-2023
Figure 6.4 Drug Addiction Product Type Sales Forecast, 2008-2023
Figure 6.5 Drug Addiction Product Type Sales Forecast and Market Share, 2008-2023
Figure 6.6 Suboxone/Subutex Sales Forecast, 2008-2023
Figure 7.1 Leading Alcohol Dependency Drug Types, 2007
Figure 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
Figure 7.3 Global Alcohol Dependency Market Forecast, 2008-2023
Figure 7.4 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
Figure 7.5 Alcohol Dependency Drug Type Sales Forecast and Market Share, 2008-2023
Figure 7.6 Campral/Aotal Sales Forecast, 2008-2023
Figure 7.7 Vivitrol Sales Forecast, 2008-2023
Figure 8.1 Leading Addiction Country Markets, 2007
Figure 8.2 Leading Addiction Country Markets, 2013
Figure 8.3 Leading Addiction Country Markets, 2018
Figure 8.4 Leading Addiction Country Markets, 2023
Figure 8.5 The US Addiction Market, 2007
Figure 8.6 US Addiction Market Sales Forecast, 2008-2023
Figure 8.7 The UK Addiction Market, 2007
Figure 8.8 UK Addiction Market Sales Forecast, 2008-2023
Figure 8.9 The French Addiction Market, 2007
Figure 8.10 French Addiction Market Sales Forecast, 2008-2023
Figure 9.1 Top-Ten Countries for Numbers of Tobacco Users
Figure 9.2 Prevalence of Obesity in Major Country Markets
Figure 9.3 Prevalence of Opioid Drug Use in Major Country Markets
Figure 9.4 Prevalence of Cocaine Use in Major Country Markets
Figure 9.5 Alcohol Consumption and Dependence in Major Country Markets